BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang K, Hu JK. Gastric cancer treatment: similarity and difference between China and Korea. Transl Gastroenterol Hepatol 2017;2:36. [PMID: 28529990 DOI: 10.21037/tgh.2017.04.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li K, Li X, Fan Y, Yang C, Lv X. Simultaneous detection of gastric cancer screening biomarkers plasma pepsinogen I/II using fluorescent immunochromatographic strip coupled with a miniature analytical device. Sensors and Actuators B: Chemical 2019;286:272-81. [DOI: 10.1016/j.snb.2019.01.149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
2 Xu D, Zhao E, Zhu C, Zhao W, Wang C, Zhang Z, Zhao G. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer. Immunobiology 2020;225:151915. [PMID: 32122675 DOI: 10.1016/j.imbio.2020.151915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, Qin S, Bai Y, Wu C, Mao Y, Wu H, Ge Y, Shen L. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond) 2019;39:38. [PMID: 31234927 DOI: 10.1186/s40880-019-0384-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cheng X, Lu Y. A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population. Future Oncol 2018;14:771-9. [PMID: 29252007 DOI: 10.2217/fon-2017-0558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Wang N, Chang LL. Maspin suppresses cell invasion and migration in gastric cancer through inhibiting EMT and angiogenesis via ITGB1/FAK pathway. Hum Cell 2020;33:663-75. [PMID: 32409959 DOI: 10.1007/s13577-020-00345-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol 2021;32:590-9. [PMID: 33609722 DOI: 10.1016/j.annonc.2021.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
7 Wang J, Yang B, Li Z, Qu J, Liu J, Song N, Chen Y, Cheng Y, Zhang S, Wang Z, Qu X, Liu Y. Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy. Ann Transl Med 2020;8:311. [PMID: 32355755 DOI: 10.21037/atm.2020.02.131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Gao M, Dang F, Deng C. β-Cryptoxanthin induced anti-proliferation and apoptosis by G0/G1 arrest and AMPK signal inactivation in gastric cancer. Eur J Pharmacol 2019;859:172528. [PMID: 31288004 DOI: 10.1016/j.ejphar.2019.172528] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhang MJ, Hong YY, Li N. Overexpression of Kin of IRRE-Like Protein 1 (KIRREL) in Gastric Cancer and Its Clinical Prognostic Significance. Med Sci Monit 2018;24:2711-9. [PMID: 29717104 DOI: 10.12659/MSM.910386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen Y, Zhang G, Chen X, Jiang X, Bie F, Yuan N, Wang Y, Hao X, Ma M. Jianpi Bushen, a Traditional Chinese Medicine Therapy, Combined with Chemotherapy for Gastric Cancer Treatment: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2018;2018:4924279. [PMID: 29675052 DOI: 10.1155/2018/4924279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021;22:1081-92. [PMID: 34252374 DOI: 10.1016/S1470-2045(21)00297-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]